Update on preventing vertical transmission of HIV type 1

American Journal of Health-System Pharmacy

Volumn 57, Issue 17, 2000, Pages 1616-1623

  Chen, Fonda ^a   Pau, Alice K ^b   Piscitelli, Stephen C ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Clinical Center Pharmacy Department   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

BONE MARROW SUPPRESSION; BREAST FEEDING; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; NEUROTOXICITY; PERINATAL INFECTION; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK FACTOR; UNITED STATES; VERTICAL TRANSMISSION;

EID: 0034284769     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.17.1616     Document Type: Review

References (41)

1. Conner EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331:1173-80.
2. Lindegren ML, Byers RH Jr, Thomas P et al. Trends in perinatal transmission of HIV-1/AIDS in the United States. JAMA. 1999; 282:531-8.
3. Bulterys M, Lepage P. Mother-to-child transmission of HIV-1. Curr Opin Pediatr. 1998; 10:143-50.
4. Mock PA, Shaffer N, Bhadrakom C et al. Maternal viral load and timing of mother-to-child HIV-1 transmission. AIDS. 1999; 13:407-14.
5. Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR. 1994; 43:1-19.
6. Berer M. Reducing perinatal HIV transmission in developing countries through antenatal and delivery care, and breastfeeding: supporting infant survival by supporting women's survival. Bull World Health Organ. 1999; 77:871-7.
7. Pitt J, Brambilla D, Reichelderfer P et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis. 1997; 175:567-75.
8. Kanada T, Shiraki K, Hirano K et al. Detection of maternofetal transfusion by placental alkaline phosphatase levels. J Pediatr. 1997; 130:730-5.
9. Mandelbrot L, Le Chenadec J, Berrebi A et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998; 280:55-60.
10. Kind C, Rudin C, Diegrist CA et al. Prevention of vertical HIV-1 transmission: additive protective effect of elective caesarian section and zidovudine prophylaxis. Swiss Neonatal HIV-1 Study Group. AIDS. 1998; 12:205-10.
11. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet. 1999; 353:1035-9.
12. International Perinatal HIV-1 Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med. 1999; 340:977-87.
13. German-Austrian guidelines for HIV-therapy during pregnancy. Eur J Med Res. 1999; 4:35-42.
14. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States, www.hivatis.org (accessed 2000 Feb 25).
15. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org (accessed 2000 Jan 28).
16. Mirochnick H, Capparelli E, Dankner W et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother. 1998; 42:808-12.
17. Eastman PS, Shapiro DE, Coombs RW et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group protocol 076. J Infect Dis. 1998; 177:557-64.
18. Kully C, Yerly S, Erb P et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect Dis. 1999; 179:705-8.
19. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR. 1995; 44:1-15.
20. Wade NA, Birkhead GS, Warren BL et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus: N Engl J Med. 1998; 339:1409-14.
21. Pedro C, Coll P, Perez MS et al. Zidovudine for prophylaxis of perinatal transmission starting on week 24 in Argentina. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC. 1997 Jan 22-26.
22. Shaffer N, Chuachoowong R, Mock PA et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999; 353:773-80.
23. Wiktor SA, Ekpini E, Karon JM et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 1999; 353:81-5.
24. DITRAME ARNS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet. 1999; 354:2050-1.
25. Silverman NS, Watts DH, Hitti J et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol. 1998; 6:237-43.
26. Grubert TA, Wintergerst U, Lutz-Friedrich R et al. Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy. AIDS. 1999; 13:1430-1.
27. Bloom SL, Dias KM, Bawdon RE et al. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol. 1997; 176:291-3.
28. Moodley J, Moodley D, Pillay K et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998; 178:1327-33.
29. Mirochnick M, Fenton T, Gagnier P et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonales. J Infect Dis. 1998; 178:368-74.
30. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354:795-802.
31. Marseille E, Kahn JG, Mmiro F et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999; 354:803-9.
32. Peters DH, Kandola K, Elmendorf AE et al. Health expenditures, services, and outcome in Africa. Basic data and cross-national comparisons, 1990-1996. Washington, DC: World Bank Human Development Network - health, nutrition, and population series; 1999.
33. Culnane M, Fowler M, Lee SS et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected women. Pediatrics AIDS Clinical Trials Group protocol 219/076 teams. JAMA. 1999; 281:151-7.
34. Hanson IC, Antonelli TA, Sperling RS et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/ neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20:463-7.
35. Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999; 354:1084-9.
36. Brinkman K, ter Hofstede HJM, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12:1735-44.
37. Sustiva package insert. Wilmington, DE: Dupont Pharmaceuticals; 1998 Sep.
38. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol. 1998; 179:758-61. Abstract.
39. Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 1998; 12:F241-7.
40. Stanworth SJ, Bolton MJ, Hay CRM et al. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia. 1998; 4:109-14.
41. Working Group on Mother-to-Infant Transmission of HIV. Rates of mother-to-infant transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immun Defic Syndr Retrovirol. 1995; 8:506-10.